675 Arapeen Drive
Salt Lake City
117 articles with Lipocine Inc.
Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy
Today announced that it has filed suit against Clarus Therapeutics, Inc. in the United States District Court alleging that Clarus's JATENZO® product infringes six of Lipocine's U.S. patents
Lipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers
Lipocine Inc., a specialty pharmaceutical company, announced acceptance of their abstract for late-breaker presentation on LPCN 1144 clinical results as part of The International Liver Congress™ 2019, the annual meeting of the European Association for the Study of the Liver.
Lipocine Inc., a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview and LPCN 1144's therapeutic potential for non-alcoholic steatohepatitis ("NASH") at the ROTH Battle of the NASH Thrones Spring Investor Conference, being held March 28, 2019 in New York City.
Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical results as part of ENDO 2019.
Lipocine Inc., a specialty pharmaceutical company, announced financial results for the year ended December 31, 2018.
Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects
Lipocine Inc. announced that the U.S. Food & Drug Administration indicated that the Phase 2 clinical study of LPCN 1144 in non-alcoholic steatohepatitis with biopsy confirmed NASH subjects may proceed in response to the Company's Investigational New Drug application.
Lipocine Inc. announced that it has filed an Investigational New Drug application ("IND") with the U.S. Food and Drug Administration ("FDA") to initiate a Phase 2 clinical study of LPCN 1144 in non-alcoholic steatohepatitis ("NASH") with biopsy confirmed NASH subjects.
Lipocine Inc. today announced approximately eight-week top-line interim results from an ongoing sixteen-week Liver Fat Imaging study ("Liver Fat Study") with LPCN 1144.
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office ("USPTO") granted Lipocine's Priority Motion in the interference case, Patent Interference No. 106,045, between Clarus Therapeutics, Inc. ("Clarus") U.S. Patent No. 8,828,428 (the "Clarus '428 Patent") and Lipocine Inc.
Lipocine, Inc. today announced completion of a definitive phlebotomy study ("Phlebotomy Study") to assess the extent, if any, of clinically meaningful ex vivo conversion of testosterone undecanoate ("TU") to testosterone ("T") in serum blood collection tubes.
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 results as part of the 2019 NASH-TAG Conference.
Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the completion of enrollment in the proof-of-concept clinical study with LPCN 1144 to assess liver fat changes in hypogonadal men at risk of developing non-alcoholic steatohepatitis
Lipocine Inc. today announced the completion of enrollment in the ambulatory blood pressure ("ABPM") clinical study for TLANDO™
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting® 2018
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 results as part of the late-breaker session of The Liver Meeting® 2018.
Lipocine Inc. announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Ladenburg Thalmann 2018 Healthcare Conference, being held October 2, 2018, at the Sofitel Hotel in New York City.
Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2018
Received a Complete Response Letter ("CRL") from the United States Food and Drug Administration ("FDA") regarding the New Drug Application ("NDA") for TLANDO™, the Company's oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism.
5/9/2018Shares of Utah-based Lipocine, Inc. are down more than 41 percent in premarket trading after the company announced it received a second Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its testosterone replacement therapy product.
Sarepta Therapeutics is breathing a little easier this morning. On Wednesday a federal appeals court supported a previous court’s decision to dismiss charges that the company misled shareholders as it vied to gain approval for its Duchenne muscular dystrophy treatment.
Specialty pharmaceutical company today announced financial results for the fourth quarter and fiscal year ended December 31, 2017.
LIPOCINE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. – LPCN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF has commenced an investigation into Lipocine Inc.